We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+15.22%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$280M
AUM Growth
+$4.87M
Cap. Flow
-$17.4M
Cap. Flow %
-6.19%
Top 10 Hldgs %
28.7%
Holding
166
New
40
Increased
28
Reduced
35
Closed
35

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$5.21M
2
ANSS
Ansys
ANSS
+$4.33M
3
JNPR
Juniper Networks
JNPR
+$4.19M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$2.49M
5
SWTX
SpringWorks Therapeutics
SWTX
+$2.36M

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$12.3M
2
IMVT icon
Immunovant
IMVT
+$5.11M
3
IMGN
Immunogen Inc
IMGN
+$4.29M
4
SPLK
Splunk Inc
SPLK
+$4.2M
5
SOVO
Sovos Brands, Inc. Common Stock
SOVO
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 44.78%
2 Technology 11.84%
3 Consumer Discretionary 7.8%
4 Industrials 6.17%
5 Financials 4.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.38B
$3M 1.07%
59,769
– –
RTX icon
27
RTX Corp
RTX
$302B
$2.96M 1.05%
30,300
+10,100
+50% +$912K
XOMA
28
DELISTED
Xoma
XOMA
$2.86M 1.02%
118,899
– –
OLMA icon
29
Olema Pharmaceuticals
OLMA
$899M
$2.81M 1%
247,880
– –
GDX icon
30
VanEck Gold Miners ETF
GDX
$27.3B
$2.78M 0.99%
+87,800
New +$2.49M
BKNG icon
31
Booking.com
BKNG
$161B
$2.75M 0.98%
18,925
+2,500
+15% +$356K
ARGX icon
32
argenx
ARGX
$54B
$2.66M 0.95%
6,745
+5,678
+532% +$2.2M
KROS icon
33
Keros Therapeutics
KROS
$210M
$2.6M 0.93%
+39,208
New +$2.32M
SWTX
34
DELISTED
SpringWorks Therapeutics
SWTX
$2.51M 0.89%
+50,987
New +$2.36M
V icon
35
Visa
V
$678B
$2.49M 0.89%
8,927
-3,400
-28% -$939K
OFIX icon
36
Orthofix Medical
OFIX
$429M
$2.44M 0.87%
+167,900
New +$2.32M
WCC
37
WESCO International
WCC
$18B
$2.43M 0.87%
14,197
+2,100
+17% +$347K
LAUR icon
38
Laureate Education
LAUR
$5.03B
$2.38M 0.85%
163,507
+21,000
+15% +$278K
CART icon
39
Maplebear
CART
$11.5B
$2.33M 0.83%
+62,400
New +$1.83M
MRC
40
DELISTED
MRC Global
MRC
$2.27M 0.81%
180,400
+28,600
+19% +$324K
IMCR icon
41
Immunocore
IMCR
$1.74B
$2.26M 0.81%
34,762
-6,865
-16% -$471K
ROIV icon
42
Roivant Sciences
ROIV
$25.5B
$2.24M 0.8%
212,118
+157,188
+286% +$1.69M
ELVN icon
43
Enliven Therapeutics
ELVN
$4.28B
$2.23M 0.8%
126,854
-10,387
-8% -$159K
META icon
44
Meta Platforms (Facebook)
META
$1.54T
$2.18M 0.78%
4,490
-2,400
-35% -$1.07M
ARVN icon
45
Arvinas
ARVN
$585M
$2.11M 0.75%
+51,122
New +$2.23M
LEGN icon
46
Legend Biotech
LEGN
$4.18B
$2.04M 0.73%
36,385
-7,920
-18% -$478K
FISV
47
Fiserv Inc
FISV
$28.1B
$2.02M 0.72%
12,653
-2,300
-15% -$335K
DVAX
48
DELISTED
Dynavax Technologies
DVAX
$1.94M 0.69%
156,161
– –
INTU icon
49
Intuit
INTU
$91.3B
$1.93M 0.69%
2,963
-200
-6% -$128K
LAD icon
50
Lithia Motors
LAD
$8.42B
$1.93M 0.69%
6,401
+1,200
+23% +$355K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return

HighVista Strategies's Q1 2024 Portfolio in Review

As of Q1 2024, HighVista Strategies held 166 positions worth $280M, up 1.8% from $276M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies withdrew a net $17.4M in Q1 2024, closing 35 positions and reducing 35 holdings. Its most notable exit was Immunovant, an estimated $5.11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Apogee Therapeutics worth $7.93M.

  • HighVista Strategies's largest Q1 2024 buy was Apogee Therapeutics: 119,403 shares worth $7.93M.
  • HighVista Strategies added most to argenx in Q1 2024, an estimated $2.2M increase.
  • HighVista Strategies's biggest Q1 2024 reduction was Spyre Therapeutics, cutting an estimated $12.3M.
  • HighVista Strategies fully exited Immunovant in Q1 2024, selling an estimated $5.11M.
  • HighVista Strategies's ten largest holdings make up 29% of its $280M portfolio in Q1 2024.
  • HighVista Strategies opened 40 new positions and closed 35 in Q1 2024.
  • HighVista Strategies's portfolio value rose 1.8% quarter-over-quarter to $280M.

Based on HighVista Strategies's 13F filing for Q1 2024, filed 15 May 2024.